Symbol:KSR2
Name:kinase suppressor of ras 2
Synonyms: FLJ25965
NCBI Gene:283455
UniProtKB Swiss-Prot: Q6VAB6

Nevi and Melanomas

Nevi and Melanomas

Nevi and Melanomas

Adenoma and adenomacarcinomas

Squamous Cell Neoplasms

F648S

E670K

L671H

G673E

G675D

F677S

R684C

Nevi and Melanomas

Gliomas, Epithelial Neoplasms, NOS

Gliomas

Nevi and Melanomas

D699N

E691D

R692W

E720D

Adenomas and Adenocarcinomas
Cystic, Mucinous and Serous Neoplasms
Epithelial Neoplasms, NOS

S702R

S731R

G744R

R818W

Ductal and lobular neoplasms

Nevi and Melanomas

Adenomas and Adenocarcinomas
Ductal and Lobular Neoplasms
Gliomas

1

1/0

1

1

1

1

1

2

1

1

2

2

2/0

0/2

1

1/1

0/1

1/0

1

1

Mutations of KSR2 have no effect on cellular localisation of KSR2, but many disrupt MAPK/ERK signalling.

Most variants were found in heterozygous form, although one severely obese individual was homozygous for two KSR2 variants (R253W and D323E).
Focused on variants that disrupt (frame-shift/nonsense) or are likely to disrupt (missense mutations in or very close to) the highly conserved kinase domain of KSR2.

Mirdametinib [PD0325901]

is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2